Document:

<PAGE>   1
                                  EXHIBIT 10.2

                               AMENDMENT NO. 1 TO
                                   AGREEMENTS
                                     BETWEEN
                                 GENELINK, INC.
                                       AND
                 UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER
                                 AT FORTH WORTH

         1. PARTIES. This AMENDMENT is made and entered into by and between
UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER AT FORTH WORTH, whose address is
3500 Camp Bowie Blvd., Forth Worth, Texas 76107-2699, hereinafter referred to as
"UNTHSC", and GENELINK, INC., a Pennsylvania corporation, with its principal
office located in Margate, New Jersey, hereinafter referred to "GeneLink".

         2. AMENDED AGREEMENTS. This is an Amendment to the DNA Specimen
Repository Agreement by and between the above listed parties dated June 21,
1995, hereinafter referred to as "AGREEMENT". A copy of the AGREEMENT is
attached hereto and incorporated by reference. In addition, this is an Amendment
to the Collateral License Agreement by and between the above listed parties
dated July 1, 1996, hereinafter referred to as "LICENSE AGREEMENT". A copy of
the LICENSE AGREEMENT is attached hereto and incorporated by reference.

         3. AMENDMENT DATE. This AMENDMENT is effective on April 1, 1996.

         4. AMENDMENT. In accordance with Section 21 of the AGREEMENT and
Section 1 of the LICENSE AGREEMENT, and for good and valuable consideration,
GeneLink and UNTHSC hereby make the following amendments:

         SECTIONS 9.1 AND 2.1 of the AGREEMENT shall be modified as follows:

                  GeneLink shall continue to pay UNTHSC [Confidential
                  Information filed separately with the Securities and Exchange
                  Commission] per client for a period of 5 years beyond the date
                  of termination of the AGREEMENT on March 21, 2001. On or about
                  April 1, 2005, the parties shall negotiate in good faith a
                  possible adjustment of this fee based upon current technology
                  and costs. Absent a written agreement signed by both parties
                  adjusting this resulting from such negotiation, all kits sold
                  under the terms of the AGREEMENT will be stored by UNTHSC in
                  accordance with the terms of the AGREEMENT at the rate of
                  [Confidential Information filed separately with the Securities
                  and Exchange Commission] per sample through March 30, 2006.

                                       1
<PAGE>   2
         SECTION 2 of the LICENSE AGREEMENT shall be replaced with the
following:

                  This LICENSE AGREEMENT shall be for the term of the AGREEMENT
                  and for the term of the AMENDMENT effective on April 1, 1996,
                  through March 30, 2006, and any other subsequent extensions.
                  This LICENSE AGREEMENT shall be subject to termination upon
                  the conditions of the AGREEMENT.

         5. CONFLICT. Other than the matters addressed above, this AMENDMENT
does not act to change or alter any other provision of the AGREEMENT or the
LICENSE AGREEMENT. In the event of a conflict between the terms of this
AMENDMENT and the AGREEMENT, the terms of this AMENDMENT will control. In the
event of a conflict between the terms of this AMENDMENT and the LICENSE
AGREEMENT, the terms of this AMENDMENT will control.

UNIVERSITY OF NORTH TEXAS               GENELINK, INC.
HEALTH CENTER AT FORT WORTH

By: /s/ David M. Richard, D.O.          By: /s/ John R. DePhillipo
    --------------------------              ----------------------
        David M. Richard, D.O.                  John R. DePhillipo
        President                               President and CEO

Date:  November 11, 1996                Date:  November 5, 1996

                                       2<PAGE>   1
                                  EXHIBIT 10.3

                          COLLATERAL LICENSE AGREEMENT

         This agreement is made and entered into as of the 1st day of July,
1996, by and between GeneLink, Inc., a Corporation of the Common wealth of
Pennsylvania, having a place of business at Margate, New Jersey (hereinafter
"Genelink"); and university of North Texas Health Science Center having a place
of business at 35 Camp Bowie Blvd., Fort Worth, Texas 76107 (hereinafter
"USTHSC").
                               W I T N E S S E T H

         Whereas, Genelink and UNTHSC have entered into a technology agreement
which was effective as of April 1, 1996 and has a termination date of March 31,
2001;

         Genelink is owner of U.S. Patent Application Serial No. 08/558,840
entitled "Non-Invasive Identification System" (hereinafter "Patent
Application");

         Accordingly, in consideration of one dollar ($1.00) and other valuable
consideration the parties agree as follows:

     1.  Subject to the terms and conditions set forth in the aforesaid
         agreement dated April 1, 1996, Genelink grants UNTHSC a royalty free
         non-exclusive license under the Patent Application.

     2.  This license shall be for the term of the technology agreement and
         subject to termination upon the same conditions set therein.

                                       1
<PAGE>   2
         IN WITNESS WHEREOF, the parties have caused this License Agreement to
be executed all as of the day and year first above written.

Attest: /s/ Patti Lloyd                 UNIVERSITY OF NORTH TEXAS
        ---------------------------
            Patti Lloyd                 HEALTH SCIENCE CENTER
            July 8, 1996

                                        By: /s/ David M. Richards, D.O.
                                            ---------------------------
                                                David M. Richards, D.O.
                                                President

Attest: /s/ Dr. Robert P. Ricciardi     GENELINK, INC.
        ---------------------------
            Dr. Robert P. Ricciardi
                  May 30, 1996

                                        By: /s/ John R. DePhillipo
                                            ---------------------------
                                                John R. DePhillipo
                                                President

                                       2<PAGE>   1
                                  EXHIBIT 10.4

                              EMPLOYMENT AGREEMENT

         EMPLOYMENT AGREEMENT("Agreement") made and entered as of February 24,
1998 by and among GENELINK, INC. (the "Company"), a New Jersey corporation and
JOHN DEPHILLIPO (the "Executive).

                                   BACKGROUND

         The parties want to enter into an employment agreement and to set forth
the terms and conditions of the Executive's employment by the Company.
Accordingly, in consideration of the mutual covenants and agreements set forth
herein and the mutual benefits to be derived herefrom, and intending to be
legally bound, the Company and the Executive agree as follows:

         1.       EMPLOYMENT.

                  (a) Duties. The Company will employ the Executive, on the
terms set forth in this Agreement, as Chairman of the Board, President and Chief
Executive Officer. The Executive accepts such employment with the Company and
will perform and fulfill such duties as are reasonable and necessary for such
position for the Company and its subsidiaries, devoting his best efforts to the
performance and fulfillment of his duties and to the advancement of the
interests of the Company, subject only to the direction, approval, control and
directives of the Board.

                  (b) Place of Performance. In his employment by the Company,
the Executive will be based in the Margate, New Jersey metropolitan area, except
for required travel on Company business.

                                       1
<PAGE>   2
         2.       TERM.

         The Executive's employment under this agreement will be for a five year
term (the "Term") commencing as of January 1, 1998 (the "Commencement Date") and
will continue uninterrupted for the Term. Each year, unless one party notified
the other party in writing by November 1 of the preceding year, on the
anniversary date of the Commencement Date, the parties will automatically extend
the Term for an additional year. The parties intend the effect that a full five
year Term will always exist under this Agreement.

         3.       COMPENSATION.

                  (a) Base Salary. During the Term, the Executive will be
entitled to receive an annual salary in the calendar year 1998 of $125,000 (the
"Base Salary"). Each year thereafter, Executive will be entitled to an increase
in the Base Salary equal to the greatest of: (i) the percentage increase in the
Consumer Price Index for the previous year as reported by the United States
Department of Commerce; (ii) 10%; or, (iii) an amount determined by the Board or
a committee of the Board designated for this purpose, payable in installments at
such time as the Company customarily pays its other senior executive employees
(but in any event no less often than monthly). The increase determined in the
previous sentence will be added to the then current Base Salary to become the
Base Salary for purposes of this Agreement.

                  (b) I there is a change in control such as would require the
Company to file a Form 8-K with the Securities and Exchange Commission if the
Company was a reporting company, the Executive will be entitled to be paid a
lump sum payment equal to the aggregate Base Salary, with minimum 10% increases
each year, for the next five years, and a lump sum bonus equal to five time the
largest bonus paid to Executive under this Agreement. The Company will pay the
payments required under the previous sentence within 30 days of the change in
control.

                                       2
<PAGE>   3
                  (c) Bonus. Executive will receive an annual bonus according to
a Company Bonus Plan adopted by the Board.

         4.       HEALTH INSURANCE AND OTHER BENEFITS.

         During the Term, the Executive will be entitled to all employee
benefits offered by the Company to its senior executives and key management
employees, including, without limitation, all pension, profit sharing,
retirement, stock option, salary continuation, deferred compensation, disability
insurance, hospitalization insurance, major medical insurance, medical
reimbursement, survivor income, life insurance or any other benefit plan or
arrangement established and maintained by the Company, subject to the rules and
regulations then in effect regarding participation therein. In addition, the
Company will obtain and fund for Executive a life insurance policy for
$1,000,000, with the beneficiary.

         5.       REIMBURSEMENT OF EXPENSES.

         The Company will reimburse Executive for all items of travel,
entertainment and miscellaneous expenses that the Executive reasonably incurs in
the performance of his duties hereunder, if the Executive submits to the Company
evidence supporting these expenses as the Company may reasonably require.

         6.       AUTOMOBILE ALLOWANCE.

         The Company will pay Executive a monthly automobile allowance of $800
for the first year of this Agreement, $800 per month for the second year and
$1000 per month thereafter, subject to increase by the Board. In the
alternative, the Company may obtain an automobile for the Executive's sole use,
to be approved by the Executive. The Company will pay directly or reimburse
Executive for all expenses of the automobile, including, but not limited to,
taxes, insurance, maintenance, fuel, parking, and the like.

                                       3
<PAGE>   4
         7.       OPTIONS:  GRANT OF SHARES.

                  (a) Upon the execution of this Agreement, the Company will
issue to Executive options to purchase 1,200,000 shares (the "Shares") of the
Company's common stock $.001 par value, exercisable at the price of $0.10 per
Share. These options will expire ten years from the date hereof and will vest as
follows:

                           (i) 400,000 Shares upon execution of this Agreement,
and

                           (ii) 200,000 Shares each January 1, beginning January
1, 1999. Options will be exercisable upon vesting. If there is a change in
control that would require the Company to file a Form 8-K with the Securities
and Exchange Commission of the Company was a reporting company, all unvested
options will be immediately exercisable. The Executive may exercise vested
options by giving the Company a note equal to the Federal Funds Rate published
in the Wall Street Journal as adjusted from time to time. In the alternative,
the Executive may use Shares owned by the Executive, valued at the
then-prevailing market price of the Shares.

                  (b) The Executive will also be eligible to participate in any
stock option, stock grant, phantom stock, or other employee incentive plan when,
as and if approved by the Board. Eligibility in no way creates an obligation of
the Company to issue options to Executive, which will be in the sole and
absolute discretion of the Compensation Committee of the Board.

                  (c) Upon execution of this Agreement. Executive will receive a
grant of 200,000 Shares as a signing bonus.

                  (d) The stock grants and options granted under this Section 7
of the Agreement will be adjusted for any recapitalizations, stock dividends,
stock splits or other changes in the Company's capital stock.

                                       4
<PAGE>   5
         8.       VACATION.

         This Agreement entitles the Executive to four weeks paid vacation in
each calendar year (prorated in any calendar year during which the Company
employs the Executive under this Agreement for less than the entire year
according to the number of days in such calendar year during which he is
employed). The Executive will also be entitled to all paid holidays given by the
Company to its senior executive officer.

         9.       TERMINATION OF EMPLOYMENT.

                  (a) Death or Total Disability. If the Executive dies during
the Term, the Agreement will end as of the date of the Executive's death. The
Company will pay the Executive's salary for the remaining Term to Executive's
beneficiary or estate, and all health insurance benefits for Executive's family
will continue for at least two years following the Executive's death. In case of
the Total Disability (as defined below) of the Executive for any consecutive
twelve months during the Term, the Company will have the right to end this
Agreement by giving the Executive thirty (30) days' prior written notice, and
upon the expiration of such thirty (30) day period, the Executive's employment
under this Agreement will end. If there is such a termination, the Company will
pay Executive his salary for the remaining Term. If the Executive will resume
his duties within thirty (30) days after receipt of such a notice of
termination, this Agreement will continue in full force and effect. Upon
termination of this Agreement under this Section 9(a), the Company will have no
further obligations or liabilities under this Agreement, except to pay to the
Executive's estate or the Executive, as the case may be, the portion of salary
that remains unpaid for the Term, including minimum increases and continuation
of benefits.

                  The term "Total Disability", as used herein, will mean a
mental or physical condition that in the reasonable opinion of an independent
medical doctor selected by the Company

                                       5
<PAGE>   6
renders the Executive unable or incompetent to carry out the material duties and
responsibilities of the Executive under this Agreement at the time the Executive
incurred the disabling condition. If the Executive is covered under any policy
or disability insurance under Section 4, the definition of Total Disability
hereunder will be the definition of that term in such policy.

                  (b) The Company may only terminate this Agreement for cause
under this Section 9(b) or under Section 9(a) of this Agreement. Cause for
termination exists only if the Executive is convicted of a felony involving
fraud or violation of the Federal Securities Laws, or a court of competent
jurisdiction finds that the Executive has engaged in conduct involving the
Company that constitutes gross negligence or intentional misconduct. If the
Company terminates the Executive under this Section, all unvested options or
stock grants will be void and the Executive will not receive any salary or
benefit continuation.

         10.      NO MITIGATION.

         This Agreement does not require the Executive to mitigate the amount of
any payment or benefit provided for in this Agreement by seeking other
employment or otherwise, nor will the amount of any payment provided for in this
Agreement be reduced by any compensation earned by the Executive as the result
of his employment by another employer.

         11.      RESTRICTIVE COVENANT.

                  (a) Competition. Executive undertakes and agrees that until
two years after termination of this Agreement, he will not compete, directly or
indirectly, or participate as a director, officer, employee, consultant agent,
consultant, representative or otherwise, or as a stockholder, partner or joint
venture, or have any direct or indirect financial interest, including, without
limitation, the interest of a creditor, in any business competing directly or
indirectly with the business of Company or any of its subsidiaries.

                                       6
<PAGE>   7
                  (b) Trade Secrets. During the Term and after termination for
any reason, Executive will not reveal, divulge, copy or otherwise use any trade
secret of the Company or its subsidiaries, it being acknowledged that all such
information and materials compiled or obtained by or disclosed to Executive
while employed by the Company or its subsidiaries hereunder or otherwise are
confidential and are the exclusive property of the Company and its subsidiaries.

                  (c) Injunctive Relief. The parties hereto agree that the
remedy at law for any breach of the provisions of this Section 11 will be
inadequate and that this Agreement entitles the Company or any of its
subsidiaries or other successors or assigns to injunctive relief without a bond.
Such injunctive relief will not be exclusive, but will be in addition to any
other rights remedies Company or any of its subsidiaries or their successors or
assigns might have for such breach.

                  (d) Scope of Covenant. Should the duration, geographical area
or range or prescribed activities contained in subparagraph (a) above be held
unreasonable by any court of competent jurisdiction, then such court may modify
the duration, geographical area or range of prescribed activities to such degree
as to make it or them reasonable and enforceable.

         12.      INDEMNIFY.

         The Company will indemnify and hold the Executive harmless to the
maximum extent permitted by law against any claim, action, demand, loss, damage,
cost, expense, liability or penalty arising out of any act, failure to act,
omission or decision by him while performing services as an officer, director or
employee of the Company, other than an act, omission or decision by the
Executive that is not in good faith and is without his reasonable belief that
the same is, or was, in the best interests of the Company. To the extent
permitted by law, the Company will pay all attorneys' fees, expenses and costs
actually incurred by the Executive in the defense of any of the claims
referenced herein.

                                       7
<PAGE>   8
         13.      MISCELLANEOUS.

                  (a) Notices. Any notice, demand or communication required or
permitted under this Agreement will be in writing and will either be hand
delivered to the other party or mailed to the addresses set forth below by
registered or certified mail, return receipt requested or sent by overnight
express mail or courier or facsimile to such address, if a party has a facsimile
machine. Notice will be deemed to have been given and received when so hand
delivered or after three business days when so deposited in the U.S. Mail, or
when transmitted and received by facsimile or sent by express mail properly
addressed to the other party. The addresses are:

                           To the Company:   GeneLink, Inc.
                                             P.O. Box 3212
                                             Margate, NJ 08402
                                             Fax No.  (609) ___-____

                           To Executive:

The parties may change the foregoing addresses at any time by written notice
given in the manner herein provided.

                  (b) Integration; Modification. This Agreement is the entire
understanding and agreement between the Company and the Executive regarding its
subject matter and supersedes all prior negotiations and agreements, whether
oral or written, between them with respect to its subject matter. This Agreement
may not be modified except by a written agreement signed by the Executive and a
duly authorized officer of the Company.

                  (c) Enforceability. If any provision of this Agreement will be
invalid or unenforceable, in whole or in part, such provision will be deemed to
be modified or restricted to the extent and in the manner necessary to render
the same valid and enforceable, or will be deemed excised from this Agreement,
as the case may be, and this Agreement will be construed and

                                       8
<PAGE>   9
enforced to the maximum extent permitted by law as if such provision had been
originally incorporated herein as so modified or restricted, or as if such
provision had not been originally incorporated herein, as the case may be.

                  (d) Binding Effect. This Agreement will be binding upon and
inure to the benefit of the parties, including and their respective heirs,
executors, successors and assigns, except that the Executive may not assign this
Agreement.

                  (e) Waiver of Breach. No waiver by either party of any
condition or of the breach by the other of any term or covenant contained in
this Agreement, whether by conduct or otherwise, in any one or more instances
will be deemed or construed as a further or continuing waiver of any such
condition or breach or a waiver of any other condition, or the breach of any
other term or covenant set forth in this Agreement. Moreover, the failure of
either party to exercise any right hereunder will not bar the later exercise of
it.

                  (f) Governing Law and Interpretation. This Agreement will be
governed by the internal laws of the State of New Jersey. Each party agrees that
he or it, as the case may be, will deal fairly and in good faith with the other
party in performing, observing and complying with the covenants, promises,
duties, obligations, terms and conditions to be performed, observed or complied
with by him or it, as the case may be, hereunder and that this Agreement shall
be interpreted, construed and enforced according to this covenant despite any
law to the contrary.

                  (g) Headings. The headings of the various sections and
paragraphs have been included herein for convenience only and will not be
considered in interpreting this Agreement.

                  (h) Counterparts. The parties may execute this Agreement in
several counterparts, each of which will be deemed to be an original but all of
which together will make up the same instrument.

                                       9
<PAGE>   10
         IN WITNESS WHEREOF, the Executive and the duly authorized officers of
the Company have executed this Agreement on the date first written above.

                                   GENELINK, INC.

                                   By: /s/ John R. DePhillipo
                                       ----------------------
                                           John R. DePhillipo

                                       /s/ John R. DePhillipo
                                       ----------------------
                                           John R. DePhillipo

                                       10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00001-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00001-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00001-of-00352.parquet"}]]